Sangamo targets Q1 2026 BLA submission for Fabry gene therapy as FDA affirms accelerated pathway
Source: SeekingAlpha
2025-11-06 23:56:42 ET
More on Sangamo Therapeutics
- Sangamo Therapeutics, Inc. (SGMO) Q3 2025 Earnings Call Transcript
- Sangamo Therapeutics GAAP EPS of -$0.11 misses by $0.11, revenue of $0.6M misses by $33.8M
- Sangamo Therapeutics Q3 2025 Earnings Preview
- Seeking Alpha’s Quant Rating on Sangamo Therapeutics
- Historical earnings data for Sangamo Therapeutics
Read the full article on Seeking Alpha
For further details see:
Sangamo targets Q1 2026 BLA submission for Fabry gene therapy as FDA affirms accelerated pathway
Sangamo Therapeutics Inc.
NASDAQ: SGMO
SGMO Trading
-0.53% G/L:
$0.4119 Last:
1,305,301 Volume:
$0.41 Open:
SGMO Latest News
March 09, 2026 08:05:00 am
Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
February 03, 2026 04:05:00 pm
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium(TM) 2026
February 03, 2026 09:10:43 am
Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering
December 18, 2025 08:05:00 am
Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
SGMO Stock Data
$133,083,570
322,698,215
1.31%
45
N/A
Biotechnology & Life Sciences
Healthcare
US
Richmond
